CAMP4 Therapeutics Corporation
CAMP · NASDAQ
12/31/2024 | 12/31/2023 | 11/30/2023 | 2/28/2023 | |
|---|---|---|---|---|
| Revenue | $0 | – | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | – | $0 | $0 |
| Gross Profit | $0 | – | $0 | $0 |
| % Margin | 100% | – | 100% | – |
| R&D Expenses | $0 | – | $0 | $0 |
| G&A Expenses | $0 | – | $0 | $0 |
| SG&A Expenses | $0 | – | $0 | $0 |
| Sales & Mktg Exp. | $0 | – | $0 | $0 |
| Other Operating Expenses | $0 | – | $0 | $0 |
| Operating Expenses | $0 | – | $0 | $0 |
| Operating Income | -$0 | – | -$0 | -$0 |
| % Margin | -8,142.3% | – | -14,822.6% | – |
| Other Income/Exp. Net | $0 | – | $0 | $0 |
| Pre-Tax Income | -$0 | – | -$0 | -$0 |
| Tax Expense | $0 | – | $0 | $0 |
| Net Income | -$0 | – | -$0 | -$0 |
| % Margin | -7,943.4% | – | -14,083.1% | – |
| EPS | -2.66 | – | -4.07 | -0.9 |
| % Growth | – | – | -352.2% | – |
| EPS Diluted | -2.66 | – | -4.07 | -0.9 |
| Weighted Avg Shares Out | 0 | – | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | – | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | – | $0 | $0 |
| Interest Expense | $0 | – | $0 | $0 |
| Depreciation & Amortization | $0 | – | $0 | $0 |
| EBITDA | -$0 | – | -$0 | -$0 |
| % Margin | -7,882.2% | – | -14,343.1% | – |